|
Post by jeremg on Dec 4, 2015 11:19:37 GMT -5
I'll say it--My biggest fail in over 30 years investing. Anyone else wanna copp? If you are in for a few years more you'll do well, in my opinion. My guess is that the covering will be done through call options -- look at the Jan open interest... If you didn't see this yet, I did a projection of sales based on the refill data we have so far... prntscr.com/9a9yyvAlmost certainly it will happen faster than this, unless SNY truly is trying to fail (that seems so completely absurd and even fradulent, not likely) My warrants are toast, unless MNKD/SNY do a Hail Mary and bump up the stock price by Feb 2016
Come on, pull an Aaron Rodgers Hail Mary PassIsn't the majority of open interest on Jan calls for strike prices above $2? I think if anything the "shorts" have exceeded there own expectations and many of these calls will expire worthless(?).
|
|
|
Post by mssciguy on Dec 4, 2015 11:21:36 GMT -5
If you are in for a few years more you'll do well, in my opinion. My guess is that the covering will be done through call options -- look at the Jan open interest... If you didn't see this yet, I did a projection of sales based on the refill data we have so far... prntscr.com/9a9yyvAlmost certainly it will happen faster than this, unless SNY truly is trying to fail (that seems so completely absurd and even fradulent, not likely) My warrants are toast, unless MNKD/SNY do a Hail Mary and bump up the stock price by Feb 2016
Come on, pull an Aaron Rodgers Hail Mary PassIsn't the majority of open interest on Jan calls for strike prices above $2? I think if anything the "shorts" have exceeded there own expectations and many of these calls will expire worthless(?). They'll have to cover sooner or later. 50-60% interest will burn a hole in anyone's pocket. Unless they have some kind of backdoor into the Federal Reserve. (would not surprise me).
|
|
|
Post by jeremg on Dec 4, 2015 11:21:43 GMT -5
Does anyone else but me that was watching the price action this morning feel like they were a witness at a crime scene? For those of us lucky enough to get in at or near the bottom, cheers! When if first opened my computer about 40min ago it was an infamous $0.005 number...
|
|
|
Post by mssciguy on Dec 4, 2015 11:29:57 GMT -5
Does anyone else but me that was watching the price action this morning feel like they were a witness at a crime scene? For those of us lucky enough to get in at or near the bottom, cheers! When if first opened my computer about 40min ago it was an infamous $0.005 number... Yeah. I hear some chatter about Renaissance and GS (of course GS, their fingerprints are everywhere). Hey, the way I see this, is if they are going to play yo-yo with the stock price, I am going to day trade it.
|
|
|
Post by jeremg on Dec 4, 2015 11:37:49 GMT -5
When if first opened my computer about 40min ago it was an infamous $0.005 number... Yeah. I hear some chatter about Renaissance and GS (of course GS, their fingerprints are everywhere). Hey, the way I see this, is if they are going to play yo-yo with the stock price, I am going to day trade it. I never learn, I thought about selling off about 10% of my holdings to day trade on the last two day runup but as usual I chose inaction. I'd almost rather just let this stock ride at this point and let fate play out, to much regret and "should haves" already under my belt with this thing.
|
|
|
Post by mnholdem on Dec 4, 2015 11:44:04 GMT -5
I got some more JAN 20 2017 4.00 Calls for only $0.30 this morning as I watched MNKD start climbing from $1.87 - it looks like there's a little more volume on the 2017 $3 calls compared to $4, but I just couldn't resist.
|
|
|
Post by sportsrancho on Dec 4, 2015 11:58:17 GMT -5
I got 100 Jan 2017 3 calls. And 50 2017 2.50
|
|
|
Post by EveningOfTheDay on Dec 4, 2015 12:06:35 GMT -5
I'll say it--My biggest fail in over 30 years investing. Anyone else wanna copp? You are certainly not alone on this. At this point I look back and I think even insiders knew how this was going to play out. Remember all those sales when the stock was flying high (even the 6s looks like a dream compared to the current sp) If you are the patient type or do not have any other option, I would say give another 2 to 4 years. I hope the trend changes before that but we could be dragged at this levels for quite a while still. I've lost it at times and tried to find farfetched reasons to what is going on, but simply put, for whatever the reasons, Afrezza is not selling right now, and that is all there is. Until we do not see a considerable increase in RXs this is where we are. The good news is that, I really believe this, Sanofi is not going anywhere and they are committed to Afrezza.
|
|
|
Post by mnholdem on Dec 4, 2015 12:08:55 GMT -5
I got 100 Jan 2017 3 calls. And 50 2017 2.50 That makes you more disciplined than me...
|
|
|
Post by frumenti on Dec 4, 2015 12:24:50 GMT -5
Having recently read an interview with Al Mann done in 2009 I think we have been overlooking one of the most important advantages Afrezza has which the possibility of eliminating the measuring and calculation of dose size at mealtime. Here is what Al said in the interview: "The advantage for all patients is that they won't have to do carb counting or anything, because Afrezza does not have to be so precisely matched to food intake." If you are not a diabetic you may not realize the significance of this comment. I started Afrezza about 3 months ago and I did not realize how important the comment was because I have never taken any insulin in any form. You do not have to prick your finger or calculate the dosage or measure the insulin you are injecting. Here is the link: www.healthline.com/diabetesmine/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mannI do not remember seeing this advantage mentioned anywhere but the advantage is huge. It is as important as "no needle". Please go to the link and read the entire interview.
|
|
|
Post by mssciguy on Dec 4, 2015 12:38:07 GMT -5
for anyone interested and fwiw, here is a screenshot of the "gang of 05" on Level 2 that a ymb poster raves about continually, supposedly appearing during manipulation errr price fixing of the common stock prntscr.com/9abec0
|
|
|
Post by slugworth008 on Dec 4, 2015 12:38:48 GMT -5
@eveningoftheday
You are certainly not alone on this. At this point I look back and I think even insiders knew how this was going to play out. Remember all those sales when the stock was flying high (even the 6s looks like a dream compared to the current sp). If you are the patient type or do not have any other option, I would say give another 2 to 4 years. I hope the trend changes before that but we could be dragged at this levels for quite a while still.
I've lost it at times and tried to find farfetched reasons to what is going on, but simply put, for whatever the reasons, Afrezza is not selling right now, and that is all there is. Until we co not see a considerable increase in RXs this is where we are. The good news is that, I really believe this, Sanofi is not going anywhere and they are committed to Afrezza. ----------------------------------------------------------------
If a true full-scale marketing campaign had been executed with TV spots - and if - the majority of endo's and PA's knew about Afrezza...then I could agree with your statement "for whatever the reasons, Afrezza is not selling right now" - However, full scale marketing has not taken place and awareness remains low among endo's and PA's - and that is why Afrezza is not selling - IMO
Virtually every aspect of this MNKD's 2015 bataan death march has been discussed "Ad nauseam".
"The good news is that, I really believe this, Sanofi is not going anywhere and they are committed to Afrezza." = I totally agree with you on this!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 4, 2015 12:39:25 GMT -5
Having recently read an interview with Al Mann done in 2009 I think we have been overlooking one of the most important advantages Afrezza has which the possibility of eliminating the measuring and calculation of dose size at mealtime. Here is what Al said in the interview: "The advantage for all patients is that they won't have to do carb counting or anything, because Afrezza does not have to be so precisely matched to food intake." If you are not a diabetic you may not realize the significance of this comment. I started Afrezza about 3 months ago and I did not realize how important the comment was because I have never taken any insulin in any form. You do not have to prick your finger or calculate the dosage or measure the insulin you are injecting. Here is the link: www.healthline.com/diabetesmine/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mannI do not remember seeing this advantage mentioned anywhere but the advantage is huge. It is as important as "no needle". Please go to the link and read the entire interview. Great point!
|
|
|
Post by tonyz on Dec 4, 2015 12:44:59 GMT -5
I got 100 Jan 2017 3 calls. And 50 2017 2.50 I have a ton of the Jan 17 and Jan 18 2 calls and 3 calls. At this stock price I've begun buying the stock and selling covered calls. I just did a trade buying 1000 shares of MNKD at 1.94 and selling the Dec 18 2.00 calls @ .12 If it's called away from me I make almost a 10% profit in 2 weeks. Or an annualized return of over 1000%. (Highly unlikely.) If the stock is not called away, I've reduced my cost to 1.82 and get to sell another 10 covered calls probably for Jan 16. The nice thing about this trade is it takes 1000 shares of MNKD out of the pool of stock the shorts can borrow. I don't loan out any of my shares. Hope our $3 2017 calls shoot up in 2016. Good luck on your trade.
|
|
|
Post by EveningOfTheDay on Dec 4, 2015 12:46:19 GMT -5
If a true full-scale marketing campaign had been executed with TV spots - and if - the majority of endo's and PA's knew about Afrezza...then I could agree with your statement "for whatever the reasons, Afrezza is not selling right now" - However, full scale marketing has not taken place and awareness remains low among endo's and PA's - and that is why Afrezza is not selling - IMO Virtually every aspect of this MNKD's 2015 bataan death march has been discussed "Ad nauseam". "The good news is that, I really believe this, Sanofi is not going anywhere and they are committed to Afrezza." = I totally agree with you on this! I fully agree with you on the reasons why Afrezza is not selling. I was just taking a shortcut and trying to avoid yet another thread about the probable pilot launch as opposed to full launch and what not. Basically I was just saying "whatever you believe are the reasons, Afrezza is not selling".
|
|